Table 1.
Demographic and clinical features of the 54 psoriatic patients.
| Variables | Patients (N = 54) |
|---|---|
| Demographic features | |
| - Mean age, years old (SD) | 42.28 (16.98) |
| - Gender | |
| Male | 29 (53.70%) |
| Female | 25 (46.30%) |
| Sex ratio (M/F) | 1.16 |
| Clinical features | |
| - Age of disease onset, years old (SD) | 30.94 (19.13) |
| Early disease onset (≤30 Years) | 30 (55.56%) |
| Late disease onset (>30 Years) | 24 (44.44%) |
| - Clinical phenotypes of psoriasis | |
| Chronic plaque psoriasis (psoriasis vulgaris) | 34 (62.97%) |
| Erythrodermic psoriasis | 14 (25.92%) |
| Pustular psoriasis | 6 (11.11%) |
| - Nail involvement | 18 (33.33%) |
| - Concomitant psoriasis arthritis | 13 (24.07%) |
| - Comorbidities | |
| Diabetes | 7 (12.96%) |
| Obesity | 5 (9.25%) |
| Hypertension | 3 (5.50%) |
| - Risk factors | |
| Stress | 37 (68.51%) |
| Smoking | 15 (27.77%) |
| Alcohol intake | 5 (9.25%) |
| - Baseline PASI | |
| Mean baseline PASI (SD) | 30.31 (12.63) |
| Moderate Psoriasis (PASI 5–10) | 1 (1.85%) |
| Severe Psoriasis (PASI > 10) | 53 (98.14%) |
| - PASI Score at week 12 of MTX | |
| Mean PASI at week 12 of MTX (SD) | 8.17 (12.97) |
| No improvement | 8 (16.32%) |
| PASI 50 | 7 (14.28%) |
| PASI 75 | 10 (20.40%) |
| PASI 90 | 9 (18.36%) |
| PASI 100 | 15 (30.61%) |
| - Tolerable side effects due to MTX | 13 (24.07%) |
| - MTX interruption due to liver and/or digestive toxicity | 4 (7.40%) |